Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler

Condition:   AsthmaInterventions:   Drug: Fp MDPI;   Drug: FS MDPI;   Drug: PlaceboSponsor:   Teva Branded Pharmaceutical Products, R&D Inc.Not yet recruiting – verified November 2016 View full post on asthma | Studies received in the last 14 days

Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and Older

Condition:   AsthmaInterventions:   Drug: Treatment A: Fp MDPI;   Drug: Treatment B: FS MDPI;   Drug: Treatment C Flovent;   Drug: Treatment D:  AdvairSponsor:   Teva Branded Pharmaceutical Products, R&D Inc.Not yet recruiting – verified May 2015 View full post on asthma | received in the last 14 days

An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma

Condition:   AsthmaInterventions:   Drug: Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler;   Drug: Placebo inhalation powders via ELLIPTA inhaler;   Drug: Fluticasone Propionate/Salmeterol 250/50 mcg via ACCUHALER/DISKUS inhaler;   Drug: Placebo inhalation powder via ACCUHALER/DISKUS inhaler;   Drug: Fluticasone…

Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma

Condition:   Persistent AsthmaInterventions:   Drug: Fluticasone propionate Multidose Dry Powder Inhaler (Fp MDPI);   Drug: Fluticasone propionate /salmeterol MDPI (FS MDPI);   Drug: Fluticasone propionate HFA Inhalation Aerosol;   Drug: Fluticasone propionate/salmeterol dry powder formulationSponsors:   Teva Pharmaceutical Industries;   Teva Branded Pharmaceutical Products, R&D Inc.Recruiting –…

A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Condition:   Pulmonary Disease, Chronic ObstructiveInterventions:   Drug: Umeclidinium bromide/Vilanterol;   Drug: Placebo ACCUHALER/DISKUS;   Drug: Fluticasone propionate/Salmeterol;   Drug: Placebo NDPISponsors:   GlaxoSmithKline;   GlaxoSmithKlineNot yet recruiting – verified April 2013 View full post on asthma | received in the last 14 days